Applies to: Renal DysfunctionThe renal elimination of tolterodine and active metabolite is limited and a prolonged half-life is not anticipated in patients with renal impairment. Applies to: Glaucoma/Intraocular HypertensionThe use of tolterodine is contraindicated in patients with uncontrolled angle-closure (narrow angle) glaucoma.

Applies to: Myasthenia Gravis. However, the pharmacokinetic disposition of tolterodine has not been evaluated in patients with renal impairment and it is recommended that tolterodine be administered cautiously in patients with compromised renal function.Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.The easiest way to lookup drug information, identify pills, check interactions and set up your own personal medication records. We comply with the HONcode standard for trustworthy health information - Major Potential Hazard, High plausibility.
However, the pharmacokinetic disposition of tolterodine has not been evaluated in patients with renal impairment and it is recommended that tolterodine be administered cautiously in patients with compromised renal function.Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.The easiest way to lookup drug information, identify pills, check interactions and set up your own personal medication records. Weakness tends to increase during periods of activity and improve after periods of rest. The effect on QT interval correlates with plasma concentration of tolterodine. Applies to: Liver DiseaseTolterodine undergoes biotransformation in the liver of extensive metabolizers to an active metabolite. Select one or more newsletters to continue. If a patient experiences anticholinergic CNS effects, dose reduction or drug discontinuation should be considered. Applies to: Dementia, CNS DisorderTolterodine is associated with anticholinergic central nervous system (CNS) effects. Tolterodine should be used with caution in patients with Parkinson's disease and in patients with preexisting dementia treated with cholinesterase inhibitors due to the risk of aggravation of symptoms.Moderate Potential Hazard, High plausibility.
Available for Android and iOS devices. I am also a 60 year old male diagnosed with myasthenia gravis. If a patient experiences anticholinergic CNS effects, dose reduction or drug discontinuation should be considered.

Tolterodine acts as a competitive antagonist of acetylcholine at postganglionic muscarinic receptors. It's caused by a breakdown in the normal communication between nerves and muscles.There's no cure for myasthenia gravis, but treatment can help relieve signs and symptoms, such as weakness of arm or leg muscles, double vision, drooping eyelids, and difficulties with speech, chewing, swall… Poor metabolizers have a greater concentration of active parent and less active metabolite, however the net activity of tolterodine is expected to be the same. Applies to: Long QT SyndromeTolterodine has been associated with QT prolongation. Many patients with this condition are treated by surgical thymectomy, using tech-niques developed by Mount Sinai physicians, including Dr. Paul Kirschner, Dr. Alan E. Kark, and the late Dr. Angelos E. Papatestas.

Tolterodine exerts anticholinergic activity and can result in increased intraocular pressure and loss of accommodation.Major Potential Hazard, High plausibility. Tolterodine tartrate should be used with caution in patients with myasthenia gravis, a disease characterized by decreased cholinergic activity at the neuromuscular junction.